Molecular Markers and Death From Prostate Cancer

  1. John Concato, MD, MPH;
  2. Dhanpat Jain, MD;
  3. Edward Uchio, MD;
  4. Harvey Risch, MD, PhD;
  5. William W. Li, MD; and
  6. Carolyn K. Wells, MPH
  1. From Veterans Affairs Clinical Epidemiology Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut; Yale University School of Medicine, New Haven, Connecticut; and the Angiogenesis Foundation, Cambridge, Massachusetts.
    1. Figure 1.
      View larger version:
        Figure 1. Study flow diagram.
      • Figure 2.
        View larger version:
          Figure 2. Estimated probability of cause-specific survival.

          Unadjusted results for bcl-2 (P < 0.001), p53 (P = 0.002), and MVD (P < 0.001) measured in quartiles of vessels per high-power microscopic field (n = 1007), excluding patients with tumors too small for staining (see text for details). hpf = high-power field; MVD = microvessel density.

        « Previous | Next Article »Table of Contents

        This Article

        1. Ann Intern Med May 5, 2009 vol. 150 no. 9 595-603
        1. AbstractFREE
        2. » Figures
        3. Full Text
        4. Full Text (PDF)

        Rapid Responses

        1. Submit a response
        2. No responses published

        Current Issue

        1. December 1, 2009, 151 (11)
        1. Alert me to current issues